FILE PHOTO: A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020. REUTERS/Brian Snyder
STAKES are high for the results of Moderna Inc.’s coming Covid-19 vaccine trial. But as far as investors are concerned, the impact may already be in the price of financial assets.
The bar was raised for markets to rally following an announcement by Pfizer Inc. that its vaccine protected 90% of Covid-19 cases in a study, investors and strategists said. Moderna’s version, which uses similar experimental messenger RNA technology, is due to report results imminently.
Already a subscriber? Log in.
Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
